## Supplemental Table 1. HSV-2 inoculation and sample collection schedule: Group 1

		•	linter				1
Days after HSV2 inoculation	HSV ineculation	convice vaginal swaha		Plood		vaginal biopsy	
		Cervico-vaginar swab	CVL	Bioou	cervical biopsy	vaginai biopsy	bionsy
0	Х	Х	Х	Х	х	Х	X
1		Х	Х	Х			
2		X	Х	Х			
3		X	X				
4		X	X	1			
6							
7	Х	Х	Х	Х	Х	Х	Х
8		Х	Х				
9		Х	Х				
10		X	X				
11		X	X	1			
13							
14	Х	Х	Х	Х			
15		Х	Х				
16		Х	Х				
17		X	X				
18		X	X	1			
20							
21	Х	Х	Х	Х	1		1
22		Х	Х				
23		Х	Х				
24		X	X				
25		X	Х				
20							
28		Х	Х	Х			
29		Х	Х				
30		Х	Х				
31		X	X				
32		X	Х				-
33							
35		Х	Х	Х			
36		X	X				
37		Х	Х				
38		X	Х				
39		X	Х				
40							
42		Х	Х	Х			
43		Х	Х				
44		Х	Х				
45		X	X	-			
46		X	X				
47							
49		Х	Х	Х			
50		Х	Х				
51		X	X				
52		X	X	<u> </u>			
53		^	^	<u> </u>			
55				ł			
56	X	XX	Х	X		<u> </u>	<u> </u>
57		X	Х				
58		X	X				
59 60		X	X				
61		^	^				
62				l	1		1
63		Х	Х	Х			
64		X	Х				
65		X	X	ļ			
66		X	X				
68		X	X	<u> </u>			
69				ł			
70		Х	Х	Х			
71		Х	Х				
72		X	Х				

a = collected twice daily in the Am and PM with an approximately a 6 hour interval

	Intervention/Sample							
	HSV inoculation	cervico-vaginal swab <sup>a</sup>	CVL <sup>a</sup>	Blood	cervical biopsy	vaginal biopsy	vulva/perineal biopsy	
0	Х	Х	Х	Х	Х	Х	X	
1		Х	Х	Х				
2		Х	Х	Х				
3		X	Х					
4		X	Х					
5								
6								
7		X	Х	Х	Х	Х	Х	
8		X	Х					
9		X	Х					
10		X	Х					
11		X	Х					
12								
13								
14		X	Х	Х				
15		X	Х					
16		X	Х					
17		X	Х					
18		X	Х					
19								
20								
21		Х	Х	Х				
22		Х	Х					
23		Х	Х					
24		X	Х					
25		Х	Х					
26								
27								
28	Х	X	Х	Х				
29		X	Х					
30		X	Х					
31		X	Х					
32		X	Х					
33								
34								
35		Х	Х	Х				
36		Х	Х					
37		Х	Х					
38		Х	Х					
39		X	Х					
40								
41								
42		Х	Х	Х				
43		Х	Х					
44		Х	Х					
45		Х	Х					
46		Х	Х					
47								
48								
49		Х	Х	Х				
50		X	Х					

## Supplemental Table 2. HSV-2 inoculation and sample collection schedule: Groups 2-5

a = collected twice daily in the Am and PM with a 4 - 6 hour interval between samples

Animal	Whole virus	Western	HerpeSelect	Luminex
Number	ELISA <sup>a</sup>	blot <sup>o</sup>	2 ELISA <sup>c</sup>	Assay <sup>a</sup>
34806	-	-	-	-
34889	-	-	-	+ <sup>e</sup>
35667	-	-	-	-
38420	-	-	-	-
33991	ND	ND	-	-
39406	ND	ND	-	+ <sup>e</sup>
33869	ND	ND	-	-
34099	ND	ND	-	-
35633	ND	ND	+	+ <sup>e</sup>
37957	ND	ND	-	-
38775	ND	ND	-	ND
38769	ND	ND	-	ND
40371	ND	ND	+	ND
33993	ND	ND	-	ND
31602	ND	ND	-	ND
38953	ND	ND	-	ND

## Supplemental Table 3. HSV-2 specific antibody responses in plasma collected from day 42-350 after HSV-2 inoculation.

a = ELISA to detect IgG antibodies to UV-inactivated disrupted HSV-2 virions. After OD values from mock virus prep coated wells were subtracted from OD values of HSV-2 coated wells, there must be a 2 fold increase in OD from the pre-inoculation sample to the post inoculation sample (> 42 days PI) for an animal to be considered positive.

b = HSV-2 western blot to detect IgG antibodies to electrophoretically separated HSV-2 proteins. There must be 3 bands at appropriate locations in the blots incubated with the post inoculation plasma sample (> 42 days PI) for an animal to be considered positive. c = HerpeSelect 2 ELISA to detect IgG antibodies to the glycoprotein G of HSV-2. There must be a 2-fold increase in OD from the preinoculation sample to the post inoculation sample (> 42 days PI) for an animal to be considered positive.

d= Luminex based assay to detect IgG antibodies to the glycoprotein J, glycoprotein D, UL25, UL19, and ICP47 of HSV-2 separately. There must be a 2 fold increase in MFI x dilution factor from the preinoculation sample to the post inoculation sample (> 42 days PI) for an animal to be considered positive.

e = The positive responses in all 3 animals was due to detection of anti-gD IgG antibodies